File S1 - In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors

Supporting information. Figure S1. Docking studies of ME36.1 and 14G2a with GD2 pentasaccharide. A. Docked model of GD2 pentasaccharide with ME36.1 Fab crystal structure. B. Docked model of GD2-pentasaccharide with 14G2a homology model. Figure S2. Electrostatic potential surfaces of 3F8, ME36.1, and 14G2a. A. Electrostatic potential surfaces of CDR regions. B. Electrostatic potential surfaces with docked GD2 pentasaccharide. Relative orientations of ceramide moieties are indicated. (DOCX)